Erythropoietin versus dextrose prolotherapy in pain relief of knee osteoarthritis

Evaluation the effect of erythropoietin versus dextrose prolotherapy in pain relief of knee osteoarthritis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016051320112N6

Enrollment

Registered

2016-06-11

Start date

2015-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthrosis of first carpometacarpal joint. Arthrosis of first carpometacarpal joint

Interventions

Intervention 1: 5 mililiter of ropivacaine 0.5% (Naropin® Fresenius Kabi USA) and 5 mililiter of dextrose 25% (Shahid ghazi, iran). Intervention 2: 5 milliliter of ropivacaine 0.5% (Naropin® Freseniu

Treatment - Drugs

5 mililiter of ropivacaine 0.5% (Naropin® Fresenius Kabi USA) and 5 mililiter of dextrose 25% (Shahid ghazi, iran)

5 milliliter of ropivacaine 0.5% (Naropin® Fresenius Kabi USA) and 4000 unite of erythropoietin (osvepoietin, osve, Tehran, iran) 2 milliliter and 3 milliliter of normal saline

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: knee osteoarthritis; 40 to 70 years of age. Exclusion criteria: addiction to alcohol or drugs; coagulopathic states such as hemophilia; rheumatoid arthritis; other verified rheumatologic diseases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: second, fourth and twelfth weeks post injection. Method of measurement: Visual Analuge Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Pooya Derakhshan

Iran University of medical sience

pooyaderakh@yahoo.com+98 21 6435 2326

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026